In light of the current global situation with COVID-19, Innovaderm’s focus is on the well-being and safety of our employees and patients, supporting business continuity for us and our customers, and ensuring that our studies continue to be conducted in compliance with applicable regulations. We are surveying health authorities, and we will continue to monitor this situation and adjust our response as may be necessary or required. Innovaderm wants to assure its sponsor and employees that contingencies plans are in place to enable business to continue as usual.


Innovaderm is following Health Canada and Centers for Disease Control (CDC) guidance and is recommending that employees work from home if they or anyone in close contact with them is exhibiting symptoms of COVID-19 or have been in contact with an affected individual.  Where possible, public transit, air and rail travel will be discouraged in regions with known outbreaks.


Face-to-face meetings are being replaced with teleconferences or video conferences, until such time as the risk of infection is reduced to acceptable levels.  For studies planning investigator meetings during the COVID-19 outbreak, it is being recommended that the study teams consider with the Sponsor conducting virtual investigator meeting rather than a physical onsite meeting.


Innovaderm will contact vendors and sites on active trials to obtain their COVID-19 business continuity plan.  Innovaderm CRAs will work with sites individually to assess whether onsite monitoring visits should be changed to offsite/remote monitoring visits to maintain oversight on quality and data integrity. Innovaderm will remain nimble and adapt monitoring resourcing strategies as required in consultation with Sponsor, IRB and Regulatory Authorities.


Innovaderm will continue to review our business continuity plan and adjust as needed. Further updates and information about Innovaderm’s response to COVID-19 will be shared on this webpage.

For COVID-19 criteria, visit the following websites:


Health Canada: